Related Experiment Videos
Pharmacological interventions for non-ulcer dyspepsia
1Gastroenterology Unit, City Hospital NHS Trust, Dudley Road, Winson Green, Birmingham, West Midlands, UK, B18 7QH.
The Cochrane Database of Systematic Reviews
|January 22, 2003
Summary
Prokinetic drugs, histamine H2 receptor antagonists (H2RAs), and proton pump inhibitors (PPIs) show effectiveness in treating non-ulcer dyspepsia (NUD). However, potential publication bias affects prokinetic and H2RA results, suggesting small effects and the need for cost-effective, well-tolerated treatments.
Area of Science:
- Gastroenterology
- Pharmacology
- Evidence-based Medicine
Background:
- Non-ulcer dyspepsia (NUD) is the most common cause of upper gastrointestinal symptoms, yet its pathophysiology and optimal treatment remain unclear.
- Significant healthcare expenditure is associated with managing dyspepsia, highlighting the need for effective therapeutic strategies.
Purpose of the Study:
- To systematically review and meta-analyze the efficacy of six drug classes in improving dyspepsia symptoms and quality of life for NUD patients.
- To compare the effectiveness of antacids, histamine H2 antagonists (H2RAs), proton pump inhibitors (PPIs), prokinetics, mucosal protecting agents, and antimuscarinics against placebo.
Main Methods:
- Comprehensive electronic database searches (CCTR, MEDLINE, EMBASE, CINAHL, SIGLE) were conducted to identify relevant randomized controlled trials (RCTs).
- Eligibility criteria included RCTs comparing any of the six drug classes against each other or placebo for NUD.
- Data extraction focused on dyspeptic symptom scores, quality of life assessments, and adverse effects.
Main Results:
- A meta-analysis of 65 RCTs (including 11796 citations initially) revealed that prokinetics (RRR 48%), H2RAs (RRR 22%), and PPIs (RRR 14%) were significantly more effective than placebo.
- Bismuth salts showed a trend towards superiority (RRR 40%) but lacked statistical significance.
- Antacids and sucralfate did not demonstrate statistically significant superiority over placebo. Publication bias may influence prokinetic and H2RA findings.
Conclusions:
- Anti-secretory therapies demonstrate potential efficacy in managing NUD.
- The interpretation of prokinetic therapy effectiveness is limited by potential publication bias.
- Future research should focus on cost-effective and well-tolerated treatments, considering the likely small effect sizes and long-term use in NUD management.